Valproic Acid Improves Antisense-Mediated Exon-Skipping Efficacy in mdx Mice
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26062583 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Micky Phongsavanh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Saclay, UVSQ, Inserm, END-ICAP, 78000 Versailles, France. Hauptthemen laut MEDLINE: Valproic Acid, Muscular Dystrophy, Duchenne, Exons, Oligonucleotides, Antisense. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Association Française contre les myopathies, the Institut National de la santé et la recherche médicale (INSERM), the Paris Ile-de-France Region.
Abstract (Originalsprache)
Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by the progressive degeneration of skeletal and cardiac muscles due to the absence of dystrophin. Exon-skipping therapy is among the most promising approaches for treating DMD, with several antisense oligonucleotides (ASO) already approved by the FDA; however, their limited efficacy highlights substantial potential for further improvement. In this study, we evaluate the potential of combining ASO with valproic acid (VPA) to enhance dystrophin expression and improve functional outcomes in a murine model of DMD. Our results indicate that the ASO+VPA treatment significantly increases dystrophin restoration across various muscle tissues, with particularly pronounced effects observed in cardiac muscle, where levels are nearly doubled compared to ASO monotherapy. Additionally, we demonstrate significant improvements in functional outcomes in treated mdx mice. Our findings suggest that the combined ASO+VPA therapy holds promise as an effective therapeutic approach to ameliorate muscle function in DMD, warranting further exploration of its mechanistic pathways and long-term benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris-Saclay, UVSQ, Inserm, END-ICAP, 78000 Versailles, France.
- Medical Biology Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco.
- LIA BAHN, CSM-UVSQ, 98000 Monaco, Monaco.
- SQY Therapeutics, UVSQ, 78180 Montigny le Bretonneux, France.
- INRAE Oniris, UMR 703 PAnTher, 44300 Nantes, France.
ORCID-Profile: Flavien Bizot, Cecile Gastaldi, Elise Brisebard, Aurélie Goyenvalle
Förderung
- Association Française contre les myopathies
- the Institut National de la santé et la recherche médicale (INSERM)
- the Paris Ile-de-France Region
- Institut National de la santé et la recherche médicale (INSERM)
- Association Monegasque contre les myopathies (AMM)
- Paris Ile-de-France Region and the Fondation UVSQ
Zitieren
APA
Phongsavanh, M., Bizot, F., Saoudi, A., Gastaldi, C., Le Coz, O., Tensorer, T., Brisebard, E., Garcia, L., & Goyenvalle, A. (2025). Valproic Acid Improves Antisense-Mediated Exon-Skipping Efficacy in mdx Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062583
Vancouver
Phongsavanh M, Bizot F, Saoudi A, Gastaldi C, Le Coz O, Tensorer T, et al. Valproic Acid Improves Antisense-Mediated Exon-Skipping Efficacy in mdx Mice. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062583
BibTeX
@article{Phongsavanh2025,
author = {Phongsavanh, Micky and Bizot, Flavien and Saoudi, Amel and Gastaldi, Cecile and Le Coz, Olivier and Tensorer, Thomas and Brisebard, Elise and Garcia, Luis and Goyenvalle, Aurélie},
title = {Valproic Acid Improves Antisense-Mediated Exon-Skipping Efficacy in mdx Mice},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26062583}
}
EUVIMED